#1 Clinical Trials Search in Europe

Tinzaparin

Tinzaparin, a low molecular weight heparin (LMWH), has been the subject of several clinical trials investigating its use in various medical conditions. These trials have explored tinzaparin’s effectiveness in preventing blood clots, treating venous thromboembolism, and potentially improving outcomes in cancer patients. This article summarizes key findings from clinical trials using tinzaparin, providing insights into its applications and safety profile across different patient populations.

Table of Contents

What is Tinzaparin?

Tinzaparin, also known by its brand name Innohep[1][2][3], is a type of medication called a low molecular weight heparin (LMWH). It belongs to a class of drugs known as anticoagulants or blood thinners. Tinzaparin is derived from a natural substance and is prepared using a special process called enzymatic hydrolysis, which gives it unique properties compared to other similar medications[3].

How Does Tinzaparin Work?

Tinzaparin works by interfering with the blood clotting process. It specifically targets certain clotting factors in your blood, making it harder for clots to form. This medication has a higher ability to block a clotting factor called Factor IIa compared to other similar drugs. It also helps release a substance called Tissue Factor Pathway Inhibitor (TFPI) from the cells lining your blood vessels, which further helps prevent clots[3].

Conditions Treated with Tinzaparin

Tinzaparin is used to treat and prevent various conditions related to blood clots, including:

  • Venous Thromboembolism (VTE): This includes deep vein thrombosis (DVT, blood clots in the deep veins, usually in the legs) and pulmonary embolism (PE, blood clots in the lungs)[4][5]
  • Prevention of VTE after surgery: Particularly in patients undergoing procedures like cesarean section or cancer surgery[1][2]
  • Cancer-associated thrombosis: Tinzaparin is often used to prevent and treat blood clots in cancer patients[5]
  • Pregnancy-related VTE: It can be used to treat and prevent blood clots during pregnancy[6]

Dosage and Administration

Tinzaparin is typically given as a subcutaneous injection, which means it’s injected just under the skin. The dose can vary depending on the condition being treated and the patient’s body weight. Some common dosing regimens include:

  • For VTE prevention after surgery: 3,500 to 4,500 IU once daily[1]
  • For VTE treatment: 175 IU per kilogram of body weight once daily[6]
  • For cancer patients: Doses may be adjusted based on body weight, typically ranging from 8,000 to 14,000 IU daily[3]

It’s important to follow your doctor’s instructions carefully when using tinzaparin.

Use in Special Populations

Tinzaparin has been studied in several special patient groups:

  • Pregnant women: Tinzaparin can be used during pregnancy to prevent and treat blood clots. The dose may need to be adjusted as the pregnancy progresses[6].
  • Patients with kidney problems: Unlike some other blood thinners, tinzaparin may be less dependent on kidney function for its clearance from the body. This means it might be safer for people with kidney problems, but more research is needed[7][4].
  • Cancer patients: Tinzaparin is often used in cancer patients to prevent and treat blood clots. Some studies are even looking at whether it might help improve survival in certain types of cancer[2][8].

Potential Side Effects

Like all medications, tinzaparin can cause side effects. The most important ones to be aware of are:

  • Bleeding: This is the most significant risk. It can range from minor bleeding (like nosebleeds or bruising easily) to major bleeding events[9].
  • Injection site reactions: You might experience some pain, redness, or bruising where the injection is given.
  • Allergic reactions: These are rare but can occur.
  • Low platelet count: In rare cases, tinzaparin can cause a condition called heparin-induced thrombocytopenia, where your platelet count drops[5].

Always inform your doctor if you experience any unusual symptoms while using tinzaparin.

Ongoing Research and Future Prospects

Researchers are continually studying tinzaparin to understand its full potential. Some areas of ongoing research include:

  • Its use in preventing blood clots in hospitalized COVID-19 patients[3]
  • Whether extended use of tinzaparin after cancer surgery might improve survival rates[2][8]
  • Its effectiveness in preventing blood clots in pregnant women with slow fetal growth[10]
  • How well it works in patients with kidney problems[7]

These studies may lead to new uses for tinzaparin in the future and help doctors understand how to use it more effectively and safely.

Trial Focus Patient Population Key Findings/Objectives
Colorectal Cancer Patients undergoing surgical resection Investigating if extended perioperative tinzaparin use improves disease-free survival
COVID-19 Hospitalized patients Evaluating intermediate or therapeutic doses for thromboprophylaxis
Pregnancy Women with intrauterine growth restriction Assessing if tinzaparin treatment increases birth weight
Renal Impairment Patients with severe chronic kidney disease Studying bioaccumulation of prophylactic tinzaparin doses
Metastatic Colorectal Cancer Patients starting first-line treatment Evaluating tinzaparin for prevention of venous thromboembolism
Pregnancy Women requiring therapeutic anticoagulation Assessing safety and efficacy of weight-based tinzaparin dosing
Renal Failure Patients with venous thromboembolism and kidney failure Investigating tinzaparin accumulation and safety in renal impairment
Cancer-Associated Thrombosis Cancer patients with venous thromboembolism Validating Ottawa score for predicting recurrence risk with tinzaparin treatment

FAQ

  • What is tinzaparin used for in clinical trials? Tinzaparin is being studied for various uses, including prevention and treatment of blood clots (venous thromboembolism), thromboprophylaxis in cancer patients, treatment of pregnant women with blood clotting disorders, and potential benefits in improving cancer-specific survival.
  • Is tinzaparin safe for patients with kidney problems? Some studies suggest that tinzaparin may be less dependent on kidney function for clearance compared to other LMWHs. However, its use in patients with severe kidney disease is still being investigated to determine the appropriate dosing and safety profile.
  • How is tinzaparin administered in clinical trials? Tinzaparin is typically administered as a subcutaneous injection. The dosage and duration of treatment vary depending on the specific condition being studied and the patient's characteristics, such as body weight and kidney function.
  • What are the potential side effects of tinzaparin? The main side effect of concern with tinzaparin, like other anticoagulants, is bleeding. Clinical trials are monitoring for both major and clinically relevant non-major bleeding events. Other potential side effects may include injection site reactions and, rarely, low platelet counts.
  • Can tinzaparin be used during pregnancy? Several clinical trials are investigating the use of tinzaparin during pregnancy, particularly for women with blood clotting disorders or at high risk of developing blood clots. These studies aim to determine the safety and effectiveness of tinzaparin for both the mother and the developing fetus.

Ongoing Clinical Trials on Tinzaparin

  • Study on Tinzaparin and Dalteparin for Patients with Venous Thromboembolism

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs (deep vein thrombosis) or lungs (pulmonary embolism).
  • Low Molecular Weight Heparin (LMWH): A class of anticoagulant medications derived from unfractionated heparin, used to prevent and treat blood clots.
  • Anti-Xa Activity: A measure of the blood's ability to inhibit clotting factor Xa, used to monitor the anticoagulant effect of LMWHs like tinzaparin.
  • Thromboprophylaxis: The prevention of blood clot formation, often through the use of anticoagulant medications.
  • Intrauterine Growth Restriction (IUGR): A condition where a fetus grows slower than expected during pregnancy, potentially leading to complications.
  • Bioaccumulation: The gradual build-up of a substance in an organism over time, which can be a concern with some medications in patients with impaired kidney function.
  • Renal Insufficiency: Reduced kidney function that may affect the body's ability to clear certain medications.
  • Clinically Relevant Non-Major Bleeding (CRNMB): Bleeding events that do not meet the criteria for major bleeding but are still considered significant in clinical trials.
  • Disease-Free Survival: The length of time after treatment during which no signs of the disease are found.
  • Ottawa Score: A clinical predictive score used to assess the risk of blood clot recurrence in cancer patients with venous thromboembolism.

References

  1. https://clinicaltrials.gov/study/NCT01321788
  2. https://clinicaltrials.gov/study/NCT01455831
  3. https://clinicaltrials.gov/study/NCT05036824
  4. https://clinicaltrials.gov/study/NCT00186745
  5. https://clinicaltrials.gov/study/NCT03099031
  6. https://clinicaltrials.gov/study/NCT00851864
  7. https://clinicaltrials.gov/study/NCT02719418
  8. https://clinicaltrials.gov/study/NCT00967148
  9. https://clinicaltrials.eu/trial/study-on-preventing-blood-clots-with-tinzaparin-in-patients-with-metastatic-colorectal-cancer-starting-first-line-treatment/
  10. https://clinicaltrials.gov/study/NCT01390051